Macdonald J S, Woolley P V, Schein P S
Recent Results Cancer Res. 1980;70:179-85. doi: 10.1007/978-3-642-81392-4_19.
Clinical strategy in chemotherapy of gastrointestinal cancer depends on availability of drugs with single-agent activity. If active drugs are available, combination chemotherapy trials can be developed. In gastric cancer, combinations of 5-fluorouracil with chloroethyl nitrosoureas or adriamycin and mitomycin C are capable of producing responses in 40-50% of patients. Such active combinations may now be evaluated in patients with less advanced gastric carcinoma. The role of combination chemotherapy is now being defined in patients with locally unresectable cancer and in the surgical adjuvant situation. In pancreatic and colorectal cancer, combination chemotherapy regimens have been of marginal effectiveness. The major thrust of clinical investigation must be directed toward phase II evaluations of single agents in these diseases.
胃肠道癌化疗的临床策略取决于具有单药活性的药物的可用性。如果有活性药物，就可以开展联合化疗试验。在胃癌中，5-氟尿嘧啶与氯乙基亚硝脲或阿霉素及丝裂霉素C联合使用，能使40%至50%的患者产生反应。现在可以在病情不太严重的胃癌患者中评估这种活性联合用药。联合化疗在局部无法切除的癌症患者和手术辅助治疗中的作用目前正在明确。在胰腺癌和结直肠癌中，联合化疗方案的效果一直很有限。临床研究的主要重点必须转向对这些疾病的单药进行II期评估。
